RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
基本信息
- 批准号:9973175
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAmyotrophic Lateral SclerosisAnimal ModelAutomobile DrivingBindingCRISPR/Cas technologyCell DeathCellsCultured CellsDepositionDiseaseDisease modelEquilibriumFeedbackFoundationsFrontotemporal Lobar DegenerationsGenetic TranscriptionGenomicsGoalsHigh-Throughput Nucleotide SequencingHomeostasisHumanIn SituIndividualInvestigationLabelLeadMaintenanceMeasuresMediatingMessenger RNAMetabolismMethodsMicroscopyModelingMolecularNerve DegenerationNeurodegenerative DisordersNeuronal DysfunctionNeuronsNeuroprotective AgentsPathogenesisPathologicPathway interactionsPatientsPhysiologic pulseProcessProsencephalonRNARNA DecayRNA DegradationRNA HelicaseRNA chemical synthesisRNA metabolismRNA-Binding ProteinsReagentRegulationRoleSeriesSpinal CordTestingTherapeuticTimeTranscriptbasedefined contributioneffective therapyfluorophorefrontotemporal lobar dementia-amyotrophic lateral sclerosisgenome editingimprovedin vivo evaluationinduced pluripotent stem cellinnovationlongitudinal analysisneuron lossneuronal survivalnovelnovel therapeuticsoverexpressionpreventprospectiveprotein TDP-43survival predictiontool
项目摘要
Abstract
Maintenance of RNA homeostasis involves a dynamic balance between RNA synthesis and turnover.
This balance is critical for transcriptionally active cells such as neurons, as disruptions to any individual
component can lead to RNA misprocessing and cell death. Our preliminary evidence indicates that deficiencies
in RNA decay represent a fundamental and heretofore unrecognized mechanism driving neuronal dysfunction
and death in the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD). Our goals with this proposal are to elucidate the role of RNA decay in the pathogenesis
of ALS and FTLD, and investigate a unique and promising therapeutic strategy affecting RNA decay. Based
upon the results of initial studies, we propose that in ALS and the most common subtype of FTLD,
characterized by neuronal deposits of the RNA binding protein TDP43, RNA homeostasis is disrupted by an
inappropriate interaction between TDP43 and the RNA helicase UPF1, ultimately resulting in
neurodegeneration. We will test this model by i) determining the impact of the TDP43-UPF1 interaction on
neuronal survival and RNA decay, ii) evaluating if deficient RNA decay is sufficient and/or necessary for
pathologic TDP43 deposition in neurons, and iii) assessing whether UPF1 expression improves neuronal
survival by restoring TDP43 and RNA homeostasis. We will pursue these aims using a combination of
longitudinal single-cell microscopy of human neurons derived from ALS and FTLD patients, CRISPR/Cas9
genome editing and high-throughput sequencing of pulse-labeled RNA. The multifaceted approach proposed
here promises to uncover key pathways controlling neuronal survival in healthy cells and in those affected by
ALS and FTLD, and will bring us one step closer to achieving our long-term goal of developing an effective
treatment for these and other relentlessly progressive neurodegenerative disorders.
摘要
维持RNA动态平衡涉及到RNA合成和周转之间的动态平衡。
这种平衡对神经元等转录活跃的细胞至关重要,对任何个体都是破坏。
成分可导致RNA错误处理和细胞死亡。我们的初步证据表明,缺陷
在RNA衰变中,代表了一种导致神经元功能障碍的基本且迄今未被认识的机制
神经退行性疾病肌萎缩侧索硬化症(ALS)和额颞叶的死亡
变性(FTLD)。我们提出这一建议的目的是阐明rna衰变在发病机制中的作用。
ALS和FTLD的研究,并研究一种影响RNA衰退的独特和有前途的治疗策略。基座
根据初步研究结果,我们认为在ALS和最常见的FTLD亚型中,
以神经元沉积RNA结合蛋白TDP43为特征,RNA动态平衡被一种
TDP43和RNA解旋酶UPF1之间的不适当相互作用,最终导致
神经退行性变。我们将通过以下方式测试这一模型:1)确定TDP43-UPF1相互作用对
神经元存活和RNA衰变,II)评估RNA衰变是否充分和/或必要
病理TDP43在神经元中的沉积,以及III)评估UPF1的表达是否改善了神经元
通过恢复TDP43和RNA动态平衡存活。我们将通过一系列措施来实现这些目标
ALS和FTLD患者来源的人类神经元的纵向单细胞显微镜,CRISPR/Cas9
基因组编辑和脉冲标记RNA的高通量测序。提出了多方面的方法
这里承诺揭示控制健康细胞和受疾病影响的神经元存活的关键途径
ALS和FTLD,并将使我们离实现开发有效的
治疗这些和其他坚持不懈的进行性神经退行性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sami Barmada其他文献
Sami Barmada的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sami Barmada', 18)}}的其他基金
Spatiotemporal analysis of TDP-43 toxicity and endolysosomal turnover mechanisms
TDP-43毒性和内溶酶体周转机制的时空分析
- 批准号:
10626673 - 财政年份:2022
- 资助金额:
$ 38.75万 - 项目类别:
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10295762 - 财政年份:2019
- 资助金额:
$ 38.75万 - 项目类别:
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10057282 - 财政年份:2019
- 资助金额:
$ 38.75万 - 项目类别:
Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS
非典型 TDP43 亚型导致 FTD/ALS 神经退行性变
- 批准号:
10534172 - 财政年份:2019
- 资助金额:
$ 38.75万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10619646 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
9324055 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10206705 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
9750843 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
肌萎缩侧索硬化症和额颞叶变性中的 RNA 衰减
- 批准号:
10435488 - 财政年份:2016
- 资助金额:
$ 38.75万 - 项目类别:
Elucidating the Mechanisms Underlying Mutant TDP43-induced Neurodegeneration
阐明突变 TDP43 诱导的神经变性的机制
- 批准号:
8725311 - 财政年份:2011
- 资助金额:
$ 38.75万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Operating Grants














{{item.name}}会员




